Miyayama Shiro, Matsui Osamu, Taki Keiichi, Minami Tetsuya, Ryu Yasuji, Ito Chiharu, Nakamura Koichi, Inoue Dai, Notsumata Kazuo, Toya Daisyu, Tanaka Nobuyoshi, Mitsui Takeshi
Department of Diagnostic Radiology, Fukuiken Saiseikai Hospital, Wadanaka-cho, Fukui 918-8503, Japan.
Cardiovasc Intervent Radiol. 2006 Jan-Feb;29(1):39-48. doi: 10.1007/s00270-004-0287-y.
To evaluate the incidence of each extrahepatic collateral pathway to hepatocellular carcinoma (HCC) and to assess technical success rates and complications of transcatheter arterial chemoembolization (TACE) through each collateral.
We retrospective evaluated extrahepatic collateral pathways to HCC on angiography in 386 procedures on 181 consecutive patients. One hundred and seventy patients had previously undergone TACE. TACE through extrahepatic collaterals using iodized oil and gelatin sponge particles was performed when a catheter was advanced into the tumor-feeding branch to avoid nontarget embolization.
A single collateral was revealed in 275 TACE procedures, two were revealed in 74, and three or more were revealed in 34. Incidences of collateral source to HCC were 83% from the right inferior phrenic artery (IPA), 24% from the cystic artery, 13% from the omental artery, 12% from the right renal capsular artery (RCA) and left IPA, 8% from the right internal mammary artery (IMA) and right intercostal artery (ICA), and 7% from the right inferior adrenal artery (IAA). Technical success rates of TACE were 53% in the right ICA, 70% in the cystic artery, 74% in the omental artery, 93% in the left IPA, 96% in the right IPA, and 100% in the right RCA, right IMA, and right IAA. Complications included skin necrosis after TACE through the right IMA (n = 1), cholecystitis after TACE through the cystic artery (n = 1), and ulcer formation after TACE through the right gastric artery (n = 1), in addition to pleural effusion and basal atelectasis after TACE through the IPA and IMA.
Our study suggests that TACE through extrahepatic collaterals is possible with high success rates, and is also relatively safe.
评估肝细胞癌(HCC)各肝外 collateral 途径的发生率,并评估经各 collateral 途径进行经动脉化疗栓塞术(TACE)的技术成功率和并发症。
我们回顾性评估了 181 例连续患者的 386 次血管造影中 HCC 的肝外 collateral 途径。170 例患者此前曾接受过 TACE。当导管进入肿瘤供血分支以避免非靶栓塞时,使用碘化油和明胶海绵颗粒通过肝外 collateral 进行 TACE。
275 次 TACE 手术中发现单一 collateral,74 次发现两个,34 次发现三个或更多。HCC 的 collateral 来源发生率分别为:右膈下动脉(IPA)83%,胆囊动脉 24%,网膜动脉 13%,右肾包膜动脉(RCA)和左 IPA 12%,右乳内动脉(IMA)和右肋间动脉(ICA)8%,右肾上腺下动脉(IAA)7%。TACE 的技术成功率在右 ICA 为 53%,胆囊动脉为 70%,网膜动脉为 74%,左 IPA 为 93%,右 IPA 为 96%,右 RCA、右 IMA 和右 IAA 为 100%。并发症包括经右 IMA 进行 TACE 后皮肤坏死(n = 1),经胆囊动脉进行 TACE 后胆囊炎(n = 1),经右胃动脉进行 TACE 后溃疡形成(n = 1),此外经 IPA 和 IMA 进行 TACE 后还有胸腔积液和基底肺不张。
我们的研究表明,通过肝外 collateral 进行 TACE 成功率高,且相对安全。